Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury
NCT05647044
Recruiting
The investigators hope to develop a treatment for suicidal ideation (SI), impulsivity and functional impairments (such as difficulties in social and work settings) that occur after a mild traumatic brain injury (mTBI). These conditions have been shown to be linked. The investigators are using a high-powered magnetic pulse, called intermittent theta burst stimulation (iTBS) applied to the head to see if it can improve these symptoms. The high-powered magnetic pulse causes certain cells in the bra... Read More
Gender:
ALL
Ages:
Between 22 years and 65 years
Trial Updated:
05/08/2025
Locations: Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois
Conditions: Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity
Register for Updates
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
NCT05650619
Recruiting
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry studies. Recent advances in the understanding of the mechanisms of FSGS in the native kidney has reinv... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Register for Updates
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988
Recruiting
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: OPN Healthcare, Inc., Glendale, California +159 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
NCT05677360
Recruiting
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Human Papilloma Virus (HPV) Vaccine
Register for Updates
A Mobile Gaming App to Improve Adherence to PrEP
NCT05762705
Recruiting
In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi. Formative evaluation interviews will be conducted with stakeholders (healthcare workers, clinic administrators, and patients taking PrEP) to inform intervention delivery. Data from the formative interviews will also be used to make necessary adaptations to the game and assess... Read More
Gender:
ALL
Ages:
Between 15 years and 34 years
Trial Updated:
05/08/2025
Locations: Boston Medical Center, Boston, Massachusetts +2 locations
Conditions: Medication Adherence, HIV/AIDS
Register for Updates
Supporting Health in Veterans With Heart Failure
NCT05839067
Recruiting
This study will test the effectiveness of a culturally-sensitive, telephone-based, tailored problem-solving intervention to improve physical and mental health in Veterans with heart failure (HF). Veterans will be recruited from VA clinics throughout the United States. As a component of this study, Veterans will partner with a registered nurse for a 12-week telehealth program that includes 8 telephone sessions. Follow-up data will be collected at 3-months (post intervention) and 6-, 12-, and 18-m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: VA Clinic - Gainesville, Gainesville, Florida +3 locations
Conditions: Heart Failure
Register for Updates
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
NCT05852717
Recruiting
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15. Patients will receive granulocyte colony stimulating factor (G-CSF) between Day 8 through Day 10 of each cycle of combination the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +3 locations
Conditions: Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Register for Updates
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
NCT05869643
Recruiting
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2025
Locations: Kaiser Permenente Los Angeles Medical Center, Los Angeles, California +12 locations
Conditions: HIV-1-infection
Register for Updates
Transcranial Alternating Current Stimulation (tACS) for the Recovery of Phonological Short-Term Memory in Patients With Aphasia After Stroke
NCT06048159
Recruiting
This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Stroke, Aphasia
Register for Updates
Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT06056791
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: VA Greater Los Angeles Healthcare System, Los Angeles, California +7 locations
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
Register for Updates
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
NCT06219174
Recruiting
The purpose of this study is to establish the safety, toxicity, and tolerability of Difluoromethylornithine (DFMO) in combination with pembrolizumab in advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Researchers also want to investigate how effective DFMO is at treating patients with advanced/ metastatic NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Non Small Cell Lung Cancer, Lung Cancer
Register for Updates
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
Recruiting
This is a Phase I/II Study to determine the safety and efficacy of Sacituzumab Govitecan and Zimberelimab with stereotactic radiation (SRS) in participants with metastatic triple negative breast cancer with brain metastases, compared to treatment with Sacituzumab Govitecan alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates